CD274 and esophageal squamous cell carcinoma: Hence, neoadjuvant PD-1/PD-L1 inhibitors in combination with chemotherapy or chemoradiotherapy are becoming a new therapeutic frontier for resectable ESCC with promising clinical outcomes.